An in-depth overview of enfortumab vedotin plus pembrolizumab, the newly approved treatment for advanced bladder cancer.
An in-depth overview of enfortumab vedotin plus pembrolizumab, the newly approved treatment for advanced bladder cancer.
A comprehensive overview of bladder cancer, including risk factors, symptoms, diagnosis, staging, grading, and treatment options.
Plain language information on interpreting a bladder cancer pathology report, focusing primarily on cancer grade and stage.
Invaluable perspectives from a panel of BCC Volunteers on diagnosis, treatment decisions, managing side effects, and coping mechanisms.
This webinar explains what UTUC is, how it’s diagnosed, the available treatments, and the latest research.
Peter will discuss his diagnosis of bladder cancer, the challenges around surgery and how he focused on goals during recovery.
This webinar discusses how CIS is different from other types of bladder cancer and why this early stage of bladder cancer needs to be treated aggressively.
4936 Yonge Street, Suite 1000, Toronto, ON M2N 6S3
Phone: 1-866-674-8889
Email & Media Contact: info@bladdercancercanada.org
Privacy Policy | Donor Bill of Rights
Charitable Reg No. 83612 6060 RR0001
© Bladder Cancer Canada.